Last month marked four years since we started Every Cure in August 2022, and we are so thankful for all of the impact that we’ve

One of the most rewarding parts of our work at Every Cure is seeing years of scientific collaboration translate into meaningful progress for patients. This

Lenalidomide/dexamethasone (len/dex) is now recommended as a preferred treatment option for patients with Rosai-Dorfman Disease regardless of mutation status, potentially expanding access to an effective,

Share this

We’re excited to share that Every Cure recently launched three new drug repurposing programs to help patients with devastating diseases that have few treatment options.

Shared commitment to ensuring patients receive the medicines they need when and where they are needed

Every Cure submitted a formal response to the FDA's Request for Information (RFI) on Drug Repurposing for Unmet Medical Needs (Docket No. FDA-2026-N-4492).

Thank you for your continued support of our mission. In addition to sharing important updates this month, we’re excited to share that we now have

Share this

We’re so pleased to highlight two important publications that build upon and reinforce our mission. In one, we worked with partners to evaluate a promising

Botulinum toxin A (BoNT/A) was surfaced in this screen as a high-ranking treatment for depression. As Many as 12 clinical studies were identified, with 7

In this newsletter, we’ll highlight the progress we’re making — for patients like Jameson, with partners like ARPA-H, and with supporters like Giorgos Tsetis —

Rosai-Dorfman-Destombes (RDD) disease is a rare histiocytic neoplasm that commonly presents with skin and subcutaneous masses, lymphadenopathy, and bone lesions. Management is guided by disease

Every Cure is deeply grateful to Giorgos Tsetis for his partnership and generous donation to our mission.

Despite the ultimate goal of medical researchers and funders being to maximize patient benefit, there is no systematic process for quantifying unmet medical need across

New phase of ARPA-H funding will support preclinical and clinical validation of AI-identified repurposing opportunities, building on earlier work that has already yielded 10 active

A decades-old drug, long used to treat conditions including a chronic parasitic disease, may soon offer new hope.. Share this

We are pleased to announce a new partnership with Every Cure. Every Cure is a U.S.-based nonprofit on a mission to save and improve lives

Dr. Fajgenbaum is being honored for his groundbreaking work advancing drug repurposing Share this

Millions of patients worldwide live with conditions that have no approved treatments or face barriers to accessing existing therapies. Every Cure, a nonprofit on a